0001564590-22-000785.txt : 20220110 0001564590-22-000785.hdr.sgml : 20220110 20220110084826 ACCESSION NUMBER: 0001564590-22-000785 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 14 CONFORMED PERIOD OF REPORT: 20220104 ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20220110 DATE AS OF CHANGE: 20220110 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Adaptive Biotechnologies Corp CENTRAL INDEX KEY: 0001478320 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 270907024 STATE OF INCORPORATION: WA FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-38957 FILM NUMBER: 22519879 BUSINESS ADDRESS: STREET 1: 1165 EASTLAKE AVE E CITY: SEATTLE STATE: WA ZIP: 98109 BUSINESS PHONE: 206-659-0067 MAIL ADDRESS: STREET 1: 1165 EASTLAKE AVE E CITY: SEATTLE STATE: WA ZIP: 98109 FORMER COMPANY: FORMER CONFORMED NAME: Adaptive TCR Corp DATE OF NAME CHANGE: 20091209 8-K 1 adpt-8k_20220104.htm 8-K adpt-8k_20220104.htm
false 0001478320 0001478320 2022-01-04 2022-01-04

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): January 4, 2022

 

ADAPTIVE BIOTECHNOLOGIES CORPORATION

(Exact name of Registrant as Specified in Its Charter)

 

 

Washington

001-38957

27-0907024

(State or Other Jurisdiction

of Incorporation)

(Commission File Number)

(IRS Employer

Identification No.)

 

 

 

1165 Eastlake Avenue East

Seattle, Washington

 

98109

(Address of Principal Executive Offices)

 

(Zip Code)

Registrant’s Telephone Number, Including Area Code: (206) 659-0067

Not Applicable

(Former Name or Former Address, if Changed Since Last Report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

 

Trading

Symbol(s)

 

Name of each exchange on which registered

Common stock, par value $0.0001 per share

 

ADPT

 

The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. 

 

 

 

 


 

 

Item 2.02

Results of Operations and Financial Condition.

 

On January 10, 2022, Adaptive Biotechnologies Corporation (the “Company”) issued a press release regarding the transition plan for the Chief Financial Officer role. The press release also stated that total revenue for the year ended December 31, 2021 is estimated to be in the range of $153 million to $154 million. A copy of the press release is attached as Exhibit 99.1 and incorporated herein by reference.

The information in this Item 2.02 and the press release attached as Exhibit 99.1 hereto shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), nor shall such information be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.

Item 5.02

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

 

Resignation of Chief Financial Officer

 

On January 4, 2022, Chad Cohen, Chief Financial Officer of the Company, notified the Company of his decision to resign as Chief Financial Officer of the Company, effective following the filing of the Company’s Annual Report on Form 10-K for the period ended December 31, 2021, on or about February 15, 2022, after which Mr. Kyle Piskel, the Company’s Principal Accounting Officer, will act as Chief Financial Officer and principal financial officer. Mr. Cohen stated that he does not have any disagreement with the Company, its management, its board of directors or any committee thereof on any matter.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

 

Exhibit

Number

 

Description

99.1

 

Press Release dated January 10, 2022

104

 

Cover Page Interactive Data File (embedded within the Inline XBRL document)

 

 


 

 

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

 

 

 

Adaptive Biotechnologies Corporation

 

 

 

 

Date: January 10, 2022

 

By:

/s/ Chad Robins

 

 

 

Chad Robins

 

 

 

Chief Executive Officer

 

 

 

EX-99.1 2 adpt-ex991_24.htm EX-99.1 adpt-ex991_24.htm

EXHIBIT 99.1

Adaptive Biotechnologies Announces Preliminary, Unaudited 2021 Revenue Results and CFO Transition

 

 

SEATTLE, Jan. 10, 2022 (GLOBE NEWSWIRE) – Adaptive Biotechnologies Corporation (Nasdaq: ADPT) today reported preliminary, unaudited revenue for the year ended December 31, 2021. Total revenue for the year ended December 31, 2021 is estimated to be in the range of $153 million to $154 million, representing an approximate increase of 56% at the mid-point of the range compared to $98.4 million for the year ended December 31, 2020.

“The Adaptive team delivered strong results in 2021, setting the stage to accelerate our immune medicine and MRD business areas,” said Chad Robins, chief executive officer and co-founder of Adaptive Biotechnologies. “Our goal is to transform the genetics of the adaptive immune system into novel diagnostics and therapeutics. We are in a strong position and poised for sustainable future growth.”

These preliminary, unaudited results are based on management’s initial analysis of operations for the year ended December 31, 2021 and are subject to change. Adaptive Biotechnologies expects to issue full financial results for the year ended December 31, 2021 on or around February 15, 2022.

Adaptive further announced that Chad Cohen, chief financial officer, will be resigning from his role, effective on or about February 15, 2022, following the filing of Adaptive Biotechnologies’ Annual Report on Form 10-K for the year ended December 31, 2021.  Adaptive Biotechnologies’ principal accounting officer, Kyle Piskel, will serve as interim CFO after Mr. Cohen’s resignation. Adaptive Biotechnologies has initiated a search for a permanent CFO with the capabilities and qualifications to help accelerate the development and commercialization of products resulting from the insights provided by its proprietary immune medicine platform. Mr. Cohen will continue to work with Adaptive Biotechnologies and Mr. Piskel in a consulting capacity to ensure a smooth transition.

“I’d like to thank Chad Cohen for his excellent contributions to both the financial and operational success at Adaptive over the last seven years,” said Chad Robins, chief executive officer and co-founder of Adaptive Biotechnologies. “We wish him all the best and we look forward to working with him through the transition.”

About Adaptive Biotechnologies
Adaptive Biotechnologies is a commercial-stage biotechnology company focused on harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. We believe the adaptive immune system is nature’s most finely tuned diagnostic and therapeutic for most diseases, but the inability to decode it has prevented the medical community from fully leveraging its capabilities. Our proprietary immune medicine platform reveals and translates the massive genetics of the adaptive immune system with scale, precision and speed to develop products in life sciences research, clinical diagnostics and drug discovery. We have three commercial products and a robust clinical pipeline to diagnose, monitor and enable the treatment of diseases such as cancer, autoimmune conditions and infectious diseases. Our goal is to develop and commercialize immune-driven clinical products tailored to each individual patient. For more information, please visit adaptivebiotech.com and follow us on www.twitter.com/adaptivebiotech.

Forward Looking Statements
This press release contains forward-looking statements that are based on management’s beliefs and assumptions and on information currently available to management. All statements contained in this release other than statements of historical fact are forward-looking statements, including statements regarding our ability to develop, commercialize and achieve market acceptance of our current and planned products and services, our research and development efforts, and other matters regarding our

 


EXHIBIT 99.1

business strategies, use of capital, results of operations and financial position, and plans and objectives for future operations.

 

In some cases, you can identify forward-looking statements by the words “may,” “will,” “could,” “would,” “should,” “expect,” “intend,” “plan,” “anticipate,” “believe,” “estimate,” “predict,” “project,” “potential,” “continue,” “ongoing” or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. These statements involve risks, uncertainties and other factors that may cause actual results, levels of activity, performance or achievements to be materially different from the information expressed or implied by these forward-looking statements. These risks, uncertainties and other factors are described under "Risk Factors," "Management's Discussion and Analysis of Financial Condition and Results of Operations" and elsewhere in the documents we file with the Securities and Exchange Commission from time to time. We caution you that forward-looking statements are based on a combination of facts and factors currently known by us and our projections of the future, about which we cannot be certain. As a result, the forward-looking statements may not prove to be accurate. The forward-looking statements in this press release represent our views as of the date hereof. We undertake no obligation to update any forward-looking statements for any reason, except as required by law.

 

MEDIA CONTACT:
Laura Cooper

205-908-5603

media@adaptivebiotech.com

 

ADAPTIVE INVESTORS:

Karina Calzadilla, Vice President, Investor Relations

201-396-1687

Carrie Mendivil, Gilmartin Group

investors@adaptivebiotech.com

 

 

GRAPHIC 3 gdhja2enbwx2000001.jpg GRAPHIC begin 644 gdhja2enbwx2000001.jpg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end EX-101.SCH 4 adpt-20220104.xsd XBRL TAXONOMY EXTENSION SCHEMA 00000 - Document - Template Link link:presentationLink link:calculationLink link:definitionLink 100000 - Document - Document and Entity Information link:calculationLink link:presentationLink link:definitionLink EX-101.LAB 5 adpt-20220104_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Entity Central Index Key Cover [Abstract] Document Type Document Type Amendment Flag Amendment Flag Document Period End Date Document Period End Date Entity Registrant Name Entity Registrant Name Entity Central Index Key Entity Incorporation, State or Country Code Entity Incorporation State Country Code Entity File Number Entity File Number Entity Tax Identification Number Entity Tax Identification Number Entity Address, Address Line One Entity Address Address Line1 Entity Address, City or Town Entity Address City Or Town Entity Address, State or Province Entity Address State Or Province Entity Address, Postal Zip Code Entity Address Postal Zip Code City Area Code City Area Code Local Phone Number Local Phone Number Written Communications Written Communications Soliciting Material Soliciting Material Pre-commencement Tender Offer Pre Commencement Tender Offer Pre-commencement Issuer Tender Offer Pre Commencement Issuer Tender Offer Title of 12(b) Security Security12b Title Trading Symbol Trading Symbol Security Exchange Name Security Exchange Name Entity Emerging Growth Company Entity Emerging Growth Company EX-101.PRE 6 adpt-20220104_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 7 R1.htm IDEA: XBRL DOCUMENT v3.21.4
Document and Entity Information
Jan. 04, 2022
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Jan. 04, 2022
Entity Registrant Name ADAPTIVE BIOTECHNOLOGIES CORPORATION
Entity Central Index Key 0001478320
Entity Incorporation, State or Country Code WA
Entity File Number 001-38957
Entity Tax Identification Number 27-0907024
Entity Address, Address Line One 1165 Eastlake Avenue East
Entity Address, City or Town Seattle
Entity Address, State or Province WA
Entity Address, Postal Zip Code 98109
City Area Code 206
Local Phone Number 659-0067
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common stock, par value $0.0001 per share
Trading Symbol ADPT
Security Exchange Name NASDAQ
Entity Emerging Growth Company false
XML 8 adpt-8k_20220104_htm.xml IDEA: XBRL DOCUMENT 0001478320 2022-01-04 2022-01-04 false 0001478320 8-K 2022-01-04 ADAPTIVE BIOTECHNOLOGIES CORPORATION WA 001-38957 27-0907024 1165 Eastlake Avenue East Seattle WA 98109 206 659-0067 false false false false Common stock, par value $0.0001 per share ADPT NASDAQ false EXCEL 9 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 10 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 11 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 12 FilingSummary.xml IDEA: XBRL DOCUMENT 3.21.4 html 1 118 1 false 0 0 false 0 false false R1.htm 100000 - Document - Document and Entity Information Sheet http://www.adaptivebiotech.com/20220104/taxonomy/role/DocumentDocumentAndEntityInformation Document and Entity Information Cover 1 false false All Reports Book All Reports adpt-8k_20220104.htm adpt-20220104.xsd adpt-20220104_lab.xml adpt-20220104_pre.xml adpt-ex991_24.htm http://xbrl.sec.gov/dei/2021 true false JSON 14 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "adpt-8k_20220104.htm": { "axisCustom": 0, "axisStandard": 0, "contextCount": 1, "dts": { "inline": { "local": [ "adpt-8k_20220104.htm" ] }, "labelLink": { "local": [ "adpt-20220104_lab.xml" ] }, "presentationLink": { "local": [ "adpt-20220104_pre.xml" ] }, "schema": { "local": [ "adpt-20220104.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.sec.gov/country/2021/country-2021.xsd", "https://xbrl.sec.gov/currency/2021/currency-2021.xsd", "https://xbrl.sec.gov/dei/2021/dei-2021.xsd", "https://xbrl.sec.gov/exch/2021/exch-2021.xsd", "http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://xbrl.sec.gov/naics/2021/naics-2021.xsd", "https://xbrl.sec.gov/sic/2021/sic-2021.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd", "https://xbrl.sec.gov/stpr/2021/stpr-2021.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd" ] } }, "elementCount": 23, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2021": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 118, "memberCustom": 0, "memberStandard": 0, "nsprefix": "adpt", "nsuri": "http://www.adaptivebiotech.com/20220104", "report": { "R1": { "firstAnchor": { "ancestors": [ "p", "body", "html" ], "baseRef": "adpt-8k_20220104.htm", "contextRef": "C_0001478320_20220104_20220104", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "100000 - Document - Document and Entity Information", "role": "http://www.adaptivebiotech.com/20220104/taxonomy/role/DocumentDocumentAndEntityInformation", "shortName": "Document and Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "p", "body", "html" ], "baseRef": "adpt-8k_20220104.htm", "contextRef": "C_0001478320_20220104_20220104", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.adaptivebiotech.com/20220104/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.adaptivebiotech.com/20220104/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2021", "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.adaptivebiotech.com/20220104/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.adaptivebiotech.com/20220104/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address Address Line1", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.adaptivebiotech.com/20220104/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address City Or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.adaptivebiotech.com/20220104/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.adaptivebiotech.com/20220104/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address State Or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.adaptivebiotech.com/20220104/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.adaptivebiotech.com/20220104/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.adaptivebiotech.com/20220104/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.adaptivebiotech.com/20220104/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "fileNumberItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation State Country Code", "terseLabel": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.adaptivebiotech.com/20220104/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.adaptivebiotech.com/20220104/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.adaptivebiotech.com/20220104/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.adaptivebiotech.com/20220104/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre Commencement Issuer Tender Offer", "terseLabel": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.adaptivebiotech.com/20220104/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre Commencement Tender Offer", "terseLabel": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.adaptivebiotech.com/20220104/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Security12b Title", "terseLabel": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.adaptivebiotech.com/20220104/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.adaptivebiotech.com/20220104/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material", "terseLabel": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.adaptivebiotech.com/20220104/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.adaptivebiotech.com/20220104/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications", "terseLabel": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.adaptivebiotech.com/20220104/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" } }, "unitCount": 0 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r5": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r6": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" } }, "version": "2.1" } ZIP 15 0001564590-22-000785-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001564590-22-000785-xbrl.zip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